Arcellx, Inc. reported significant financial results for the third quarter of 2025, revealing a collaboration revenue of $4.9 million, a substantial decrease from $26.0 million in the same period last year. For the nine months ending September 30, 2025, total collaboration revenue was $20.6 million, down from $92.7 million in 2024. The decline in revenue is attributed to the completion of dosing and manufacturing of the company's lead product candidate, anito-cel, in the iMMagine-1 trial, which concluded in late 2024. The company incurred a net loss of $55.8 million for the quarter, compared to a loss of $25.9 million in the prior year, and a net loss of $170.8 million for the nine-month period, up from $60.3 million in 2024.
Operating expenses for the third quarter totaled $66.7 million, an increase from $59.6 million in the same quarter of 2024. This rise was primarily driven by a $11.2 million increase in general and administrative expenses, which included higher costs related to commercial readiness and personnel. Research and development expenses decreased to $35.1 million from $39.2 million, reflecting reduced external costs associated with the anito-cel program. The company’s accumulated deficit reached $667.7 million as of September 30, 2025.
In terms of strategic developments, Arcellx has continued its collaboration with Kite Pharma, a Gilead company, under the Kite Collaboration Agreement. The partnership has expanded to include additional product candidates and indications, with Kite having made significant equity investments in Arcellx. The company is also advancing its clinical programs, including the pivotal Phase 2 iMMagine-1 trial and the Phase 3 iMMagine-3 trial for anito-cel, as well as developing two ARC-SparX programs targeting different hematologic cancers.
As of September 30, 2025, Arcellx reported cash, cash equivalents, and marketable securities totaling $576.0 million, which management believes will be sufficient to fund operations into 2028. The company anticipates continued significant operating losses as it advances its clinical programs and prepares for potential commercialization of its product candidates. Looking ahead, Arcellx plans to expand its pipeline and may require additional funding to support its ongoing operations and development efforts. The company has not yet generated revenue from product sales and does not expect to do so until it receives regulatory approval for its product candidates.
About Arcellx, Inc.
Arcellx, Inc. is a clinical-stage biotechnology company developing innovative cell therapies using its proprietary D-Domain platform to create safer, more effective, and broadly accessible CAR-T treatments. Its core products include ddCARs—single infusion CAR-T therapies—and ARC-SparX, a controllable universal CAR-T system. Targeting hematologic cancers, solid tumors, and autoimmune diseases, Arcellx leverages engineered synthetic binding domains to improve efficacy, safety, manufacturability, and treatment adaptability.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.